Zizi Yu is a Dermatology physician affiliated with Boston University. OpenAlex indexes 44 publications with 566 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20252 payments
- Incyte CorporationProgram year20252 payments
- GENZYME CORPORATIONProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
34.8%Corticosteroid26.5%Triamcinolone Acetonide100%Part D≥24 patientsInterleukin-4 Receptor alpha Antagonist8.4%Dupixent Pen100%Part D<11 patientsAnti-infectives
32.3%Azole Antifungal25.2%Ketoconazole100%Part D≥20 patientsLincosamide Antibacterial7.1%Clindamycin Phosphate100%Part D<11 patientsSensory organs
14.2%Corticosteroid14.2%Betamethasone Diprop Augmented100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prospective Pilot Evaluation of the Safety, Tolerability, and Efficacy of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel plus Clascoterone 1% Cream in Adult Patients with Acne.
PubMed
2025 - Phototherapy Restores Deficient Type I IFN Production and Enhances Antitumor Responses in Mycosis Fungoides
Journal of Investigative Dermatology
2023 - Improving dermatology residency program website transparency in the era of preference signaling
Dermatology Online Journal
2022 - Financial worry and psychological distress among cancer survivors in the United States, 2013—2018
Supportive Care in Cancer
2021 - 3D Printed frames to enable reuse and improve the fit of N95 and KN95 respirators
BMC Biomedical Engineering
2021
Similar KOLs
Other experts from the same institution or the same specialty.
David Felson, MD
Boston University
Gary Balady, MD
Boston University
Andrew Budson, MD
Boston University
Davidson Hamer, MD
Boston University
Robert Modlin, MD
University of California, Los Angeles
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”